# A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis

> **NCT05014438** · PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 17 (actual)

## Conditions studied

- Dermatitis, Atopic

## Interventions

- **DRUG:** BMS-986166
- **DRUG:** Branebrutinib
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05014438
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-08-17
- **Primary completion:** 2022-08-22
- **Final completion:** 2022-08-22
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2023-10-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05014438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05014438, "A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05014438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*